As of close of business last night, Seelos Therapeutics Inc’s stock clocked out at $0.39, down -11.67% from its previous closing price of $0.44. On the day, 547289 shares were traded.
Ratios:
To gain a deeper understanding of SEEL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.14 and its Current Ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, ROTH Capital on September 27, 2021, Upgraded its rating to Buy and sets its target price to $8 from $2.50 previously.
On July 01, 2021, Guggenheim started tracking the stock assigning a Buy rating and target price of $8.
On June 01, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $10.Cantor Fitzgerald initiated its Overweight rating on June 01, 2021, with a $10 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 01 ’23 when Mehra Raj bought 75,757 shares for $1.32 per share. The transaction valued at 99,999 led to the insider holds 185,142 shares of the business.
Golembiewski Michael Joseph bought 83,000 shares of SEEL for $100,222 on Nov 30 ’23. The Chief Financial Officer now owns 86,450 shares after completing the transaction at $1.21 per share.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.39.
Stock Price History:
Over the past 52 weeks, SEEL has reached a high of $49.80, while it has fallen to a 52-week low of $0.37.
Shares Statistics:
A total of 13.68M shares are outstanding, with a floating share count of 12.49M. Insiders hold about 8.70% of the company’s shares, while institutions hold 13.12% stake in the company.
Earnings Estimates
As of right now, 1 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$1.48 for the current quarter, with a high estimate of -$1.48 and a low estimate of -$1.48, while EPS last year was -$3.6. The consensus estimate for the next quarter is -$1.19, with high estimates of -$1.19 and low estimates of -$1.19.
Analysts are recommending an EPS of between -$4.09 and -$4.09 for the fiscal current year, implying an average EPS of -$4.09. EPS for the following year is $0, with — analysts recommending between $0 and $0.
Revenue Estimates
In the current quarter, 1 analysts expect revenue to total $300k. It ranges from a high estimate of $300k to a low estimate of $300k. As of the current estimate, Seelos Therapeutics Inc’s year-ago sales were $808k, an estimated decrease of -62.90% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $300k, a decrease of -10.70% over than the figure of -$62.90% in the same quarter last year. There is a high estimate of $300k for the next quarter, whereas the lowest estimate is $300k.
